Award
NIH Reporter #1R21AR088602-01
An Oleoyl Serine Derivative as an Innovative Therapeutic Approach for Osteoporosis
Recipient
Beth Israel Deaconess Medical Center, Boston, MA, United States
Award Amount
$430,816.00
Ceiling
$430,816.00
Awarded
September 17, 2026
Identifier
1R21AR088602-01
Award for developing an oral nutraceutical compound to prevent osteoporosis-related bone loss in female mice, evaluating efficacy through various administration methods and bone health assessments.
Description
This project aims to develop a safe, oral nutraceutical compound derived from olive oil, oleoyl -methyl serine (HU-671), to prevent osteoporosis-related bone loss in female mice. The study will evaluate the efficacy of HU-671 administered via oral gavage and intraperitoneal injection, assessing bone mass, microstructure, strength, and gene expression pathways.